phrykt

Castle Biosciences Inc (CSTL): who owns it and who trades it

As of Nov 16, 2026, CSTL insiders reported 170 open-market sales worth $18.9M and no purchases in the last 12 months, with 83% of the sale value made under pre-set 10b5-1 plans. The largest seller was Derek J Maetzold (Director), with $11.6M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Castle Biosciences

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CSTL

177 funds and institutions reported CSTL shares worth $696M at the end of Q2 2026, about 94% of the company. The largest holder is BlackRock, Inc. with 10.9%.

Funds and institutions (13F) 94%Everyone else 6%

10 largest owners, by share of the company

BlackRock, Inc.10.9%
Rtw Investments, LP9.2%
Principal Financial Group Inc5.7%
Vanguard Capital Management LLC4.0%
Acadian Asset Management LLC3.0%
California State Teachers Retirement System3.0%
Vanguard Portfolio Management LLC2.8%
Summit Partners Public Asset Management, LLC2.7%
State Street Corp2.7%
Allianz Asset Management GmbH2.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.3.29M10.85%$78.5M+10%
Rtw Investments, LP2.78M9.16%$66.3M+1%
Principal Financial Group Inc1.73M5.69%$41.2M-2%
Vanguard Capital Management LLC1.23M4.04%$29.3M+4%
Acadian Asset Management LLC918,6683.03%$21.9M+90%
California State Teachers Retirement System901,5782.97%$37.8M+3177%
Vanguard Portfolio Management LLC840,7852.77%$20.1M-2%
Summit Partners Public Asset Management, LLC824,8722.72%$19.7M-12%
State Street Corp822,0792.71%$19.6M+7%
Allianz Asset Management GmbH811,3242.67%$19.9MNo change
Geode Capital Management, LLC795,9122.62%$19M+9%
Mackenzie Financial Corp793,5072.62%$18.9M+971%
Dimensional Fund Advisors LP791,0852.61%$18.9M-24%
Jefferies Financial Group Inc.647,3912.13%$15.4M–
Qube Research & Technologies Ltd589,3001.94%$14.1M+5%
AIGH Capital Management LLC545,1011.80%$13M-8%
Renaissance Technologies LLC371,2001.22%$8.9M-30%
Goldman Sachs Group Inc358,3971.18%$8.5M+5%
Point72 Asset Management, L.P.357,3171.18%$8.5M–
Kennedy Capital Management LLC348,3711.15%$8.3M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CSTL insiders reported $0 of open-market purchases and $18.9M of sales. 83% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$18.9M
170 trades, 5 people
Sales under a 10b5-1 plan
83%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$4.9M$4.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Tobin W JuvenalChief Commercial OfficerSale3,195$35.07$112KForm 4
Nov 11, 2026Tobin W JuvenalChief Commercial OfficerSale plan2,828$35.04$99.1KForm 4
Nov 9, 2026Tobin W JuvenalChief Commercial OfficerSale plan3,288$32.67$107KForm 4
Nov 2, 2026Derek J MaetzoldDirectorSale plan7,555$36.01$272KForm 4
Nov 2, 2026Derek J MaetzoldDirectorSale plan2,816$36.01$101KForm 4
Nov 2, 2026Derek J MaetzoldDirectorSale plan2,393$36.01$86.2KForm 4
Nov 2, 2026Derek J MaetzoldDirectorSale plan1,025$36.81$37.7KForm 4
Nov 2, 2026Derek J MaetzoldDirectorSale plan382$36.81$14.1KForm 4
Nov 2, 2026Derek J MaetzoldDirectorSale plan325$36.81$12KForm 4
Oct 28, 2026Tobin W JuvenalChief Commercial OfficerSale plan1,237$35.58$44KForm 4
Oct 28, 2026Tobin W JuvenalChief Commercial OfficerSale plan5,341$36.62$196KForm 4
Oct 26, 2026Tobin W JuvenalChief Commercial OfficerSale plan3,288$33.08$109KForm 4
Oct 19, 2026Derek J MaetzoldDirectorSale plan8,580$31.91$274KForm 4
Oct 19, 2026Derek J MaetzoldDirectorSale plan3,198$31.91$102KForm 4
Oct 19, 2026Derek J MaetzoldDirectorSale plan2,718$31.91$86.7KForm 4
Oct 12, 2026Tobin W JuvenalChief Commercial OfficerSale plan3,288$33.64$111KForm 4
Oct 5, 2026Derek J MaetzoldDirectorSale plan8,580$35.57$305KForm 4
Oct 5, 2026Derek J MaetzoldDirectorSale plan3,198$35.57$114KForm 4
Oct 5, 2026Derek J MaetzoldDirectorSale plan2,718$35.57$96.7KForm 4
Oct 1, 2026Kristen M OelschlagerChief Operating OfficerSale plan2,807$35.75$100KForm 4
Oct 1, 2026Kristen M OelschlagerChief Operating OfficerSale plan1,346$36.38$49KForm 4
Sep 30, 2026Tobin W JuvenalChief Commercial OfficerSale plan1,034$34.20$35.4KForm 4
Sep 29, 2026Tobin W JuvenalChief Commercial OfficerSale plan5,543$35.50$197KForm 4
Sep 21, 2026Derek J MaetzoldDirectorSale plan2,718$35.33$96KForm 4
Sep 21, 2026Derek J MaetzoldDirectorSale plan3,198$35.33$113KForm 4
Sep 21, 2026Derek J MaetzoldDirectorSale plan8,580$35.33$303KForm 4
Sep 15, 2026Tobin W JuvenalChief Commercial OfficerSale plan3,294$35.14$116KForm 4
Sep 14, 2026Tobin W JuvenalChief Commercial OfficerSale plan3,306$32.32$107KForm 4
Sep 11, 2026Derek J MaetzoldDirectorSale plan8,361$32.00$268KForm 4
Sep 11, 2026Derek J MaetzoldDirectorSale plan3,124$32.00$100KForm 4
Sep 11, 2026Derek J MaetzoldDirectorSale plan2,656$32.00$85KForm 4
Sep 11, 2026Derek J MaetzoldDirectorSale plan71$32.78$2.3KForm 4
Sep 11, 2026Derek J MaetzoldDirectorSale plan83$32.78$2.7KForm 4
Sep 11, 2026Derek J MaetzoldDirectorSale plan223$32.78$7.3KForm 4
Sep 1, 2026Kristen M OelschlagerChief Operating OfficerSale plan200$34.02$6.8KForm 4
Sep 1, 2026Kristen M OelschlagerChief Operating OfficerSale plan3,952$33.36$132KForm 4
Aug 31, 2026Tobin W JuvenalChief Commercial OfficerSale plan1,730$32.81$56.8KForm 4
Aug 28, 2026Derek J MaetzoldDirectorSale plan2,505$33.14$83KForm 4
Aug 28, 2026Derek J MaetzoldDirectorSale plan2,129$33.14$70.6KForm 4
Aug 28, 2026Derek J MaetzoldDirectorSale plan257$33.14$8.5KForm 4
Aug 28, 2026Derek J MaetzoldDirectorSale plan21$33.88$711Form 4
Aug 28, 2026Derek J MaetzoldDirectorSale plan956$33.88$32.4KForm 4
Aug 28, 2026Derek J MaetzoldDirectorSale plan209$33.88$7.1KForm 4
Aug 28, 2026Derek J MaetzoldDirectorSale plan177$33.88$6KForm 4
Aug 28, 2026Derek J MaetzoldDirectorSale plan11,472$33.14$380KForm 4
Aug 25, 2026Tobin W JuvenalChief Commercial OfficerSale plan9,050$35.04$317KForm 4
Aug 25, 2026Kristen M OelschlagerChief Operating OfficerSale7,161$34.26$245KForm 4
Aug 25, 2026Kristen M OelschlagerChief Operating OfficerSale5,223$34.64$181KForm 4
Aug 24, 2026Kristen M OelschlagerChief Operating OfficerSale12,218$33.69$412KForm 4
Aug 17, 2026Tobin W JuvenalChief Commercial OfficerSale plan1,730$29.59$51.2KForm 4
Aug 14, 2026Frank StokesCFOSale24,908$29.77$742KForm 4
Aug 14, 2026Derek J MaetzoldDirectorSale plan1,100$30.02$33KForm 4
Aug 14, 2026Derek J MaetzoldDirectorSale plan2,714$30.02$81.5KForm 4
Aug 14, 2026Derek J MaetzoldDirectorSale plan2,306$30.02$69.2KForm 4
Aug 14, 2026Derek J MaetzoldDirectorSale plan278$30.02$8.3KForm 4
Aug 5, 2026Derek J MaetzoldDirectorSale plan2,546$30.68$78.1KForm 4
Aug 5, 2026Derek J MaetzoldDirectorSale plan556$30.68$17.1KForm 4
Aug 5, 2026Derek J MaetzoldDirectorSale plan473$30.68$14.5KForm 4
Aug 4, 2026Derek J MaetzoldDirectorSale plan11,935$31.34$374KForm 4
Aug 4, 2026Derek J MaetzoldDirectorSale plan4,782$31.34$150KForm 4
Aug 4, 2026Derek J MaetzoldDirectorSale plan4,063$31.34$127KForm 4
Aug 4, 2026Derek J MaetzoldDirectorSale plan2,866$30.79$88.2KForm 4
Aug 4, 2026Derek J MaetzoldDirectorSale plan3,374$30.79$104KForm 4
Aug 4, 2026Derek J MaetzoldDirectorSale plan8,421$30.79$259KForm 4
Aug 3, 2026Kristen M OelschlagerChief Operating OfficerSale plan1,100$30.62$33.7KForm 4
Aug 3, 2026Kristen M OelschlagerChief Operating OfficerSale plan3,000$29.12$87.4KForm 4
Aug 3, 2026Kristen M OelschlagerChief Operating OfficerSale plan4,486$30.00$135KForm 4
Aug 3, 2026Tobin W JuvenalChief Commercial OfficerSale plan1,730$28.25$48.9KForm 4
Aug 3, 2026Derek J MaetzoldDirectorSale plan4,232$30.35$128KForm 4
Aug 3, 2026Derek J MaetzoldDirectorSale plan10,664$30.35$324KForm 4
Aug 3, 2026Derek J MaetzoldDirectorSale plan3,597$30.35$109KForm 4
Jul 31, 2026Tobin W JuvenalChief Commercial OfficerSale plan1,891$30.26$57.2KForm 4
Jul 31, 2026Tobin W JuvenalChief Commercial OfficerSale plan8,149$28.84$235KForm 4
Jul 31, 2026Tobin W JuvenalChief Commercial OfficerSale plan7,270$29.58$215KForm 4
Jul 31, 2026Derek J MaetzoldDirectorSale plan1,690$30.15$51KForm 4
Jul 31, 2026Derek J MaetzoldDirectorSale plan6,480$30.15$195KForm 4
Jul 31, 2026Derek J MaetzoldDirectorSale plan1,983$30.15$59.8KForm 4
Jul 27, 2026Derek J MaetzoldDirectorSale plan43$25.06$1.1KForm 4
Jul 27, 2026Derek J MaetzoldDirectorSale plan10$25.06$251Form 4
Jul 27, 2026Derek J MaetzoldDirectorSale plan5,982$24.13$144KForm 4
Jul 27, 2026Derek J MaetzoldDirectorSale plan1,307$24.13$31.5KForm 4
Jul 27, 2026Derek J MaetzoldDirectorSale plan1,110$24.13$26.8KForm 4
Jul 27, 2026Derek J MaetzoldDirectorSale plan268$24.13$6.5KForm 4
Jul 27, 2026Derek J MaetzoldDirectorSale plan232$25.06$5.8KForm 4
Jul 27, 2026Derek J MaetzoldDirectorSale plan50$25.06$1.3KForm 4
Jul 14, 2026Derek J MaetzoldDirectorSale plan550$22.92$12.6KForm 4
Jul 14, 2026Derek J MaetzoldDirectorSale plan1,357$22.92$31.1KForm 4
Jul 14, 2026Derek J MaetzoldDirectorSale plan278$22.92$6.4KForm 4
Jul 14, 2026Derek J MaetzoldDirectorSale plan1,153$22.92$26.4KForm 4
Jul 1, 2026Derek J MaetzoldDirectorSale plan1,357$24.29$33KForm 4
Jul 1, 2026Derek J MaetzoldDirectorSale plan1,153$24.29$28KForm 4
Jul 1, 2026Derek J MaetzoldDirectorSale plan278$24.29$6.8KForm 4
Jul 1, 2026Derek J MaetzoldDirectorSale plan6,214$24.29$151KForm 4
Jul 1, 2026Kristen M OelschlagerChief Operating OfficerSale plan8,186$24.40$200KForm 4
Jul 1, 2026Kristen M OelschlagerChief Operating OfficerSale plan400$24.78$9.9KForm 4
Jun 16, 2026Kristen M OelschlagerChief Operating OfficerSale plan8,587$20.71$178KForm 4
Jun 15, 2026Derek J MaetzoldDirectorSale plan550$20.66$11.4KForm 4
Jun 15, 2026Derek J MaetzoldDirectorSale plan1,357$20.66$28KForm 4
Jun 15, 2026Derek J MaetzoldDirectorSale plan1,153$20.66$23.8KForm 4
Jun 15, 2026Derek J MaetzoldDirectorSale plan278$20.66$5.7KForm 4

Latest 100 of 170 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Derek J MaetzoldPres. & Chief Exec. Officer, Director–$11.6MNov 2, 2026
Tobin W JuvenalChief Commercial Officer–$3.5MNov 11, 2026
Kristen M OelschlagerChief Operating Officer–$2.4MOct 1, 2026
Frank StokesChief Financial Officer–$1.3MAug 14, 2026
G Bradley ColeDirector–$211KMar 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CSTL short interest

Moderate short interest. 6.8% of CSTL shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 49%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.11M CSTL shares were sold short, 6.8% of the shares outstanding, up 4.6% from the report before. At the average daily volume of 347,929 shares, buying them all back would take about 6.1 trading days (days to cover).

Shares short, % of all shares

6.84%May 15Oct 307.17%

Days to cover

6.1May 15Oct 308.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.11M6.84%+5%347,9296.1
Oct 15, 20262.02M6.60%+1%337,0536.0
Sep 30, 20262.00M6.55%+5%419,6334.8
Sep 15, 20261.90M6.22%-4%257,9377.4
Aug 31, 20261.98M6.47%+13%391,4375.0
Aug 14, 20261.75M5.74%+12%477,0953.7
Jul 31, 20261.56M5.11%+10%491,9793.2
Jul 15, 20261.42M4.69%-5%251,0975.7
Jun 30, 20261.49M4.92%+0%469,0053.2
Jun 15, 20261.49M4.90%No change284,2225.2
May 29, 20261.48M4.90%+5%393,0313.8
May 15, 20261.42M4.67%-1%633,8712.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Castle Biosciences company events

Castle Biosciences filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Jul 30, 2026ResultsReleased financial results. Filing
  3. May 29, 2026VoteReported shareholder vote results. Filing
  4. May 6, 2026ResultsReleased financial results. Filing
  5. Feb 26, 2026ResultsReleased financial results. Filing
  6. Jan 13, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Castle Biosciences financials

Famous investors that hold CSTL

4 of the 50 well-known investors we track reported holding CSTL in their latest 13F filing. The largest position is Israel Englander's, worth $17.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026495,633$17.6M0.0%+141%
Jim Simons · Renaissance TechnologiesQ3 2026322,400$11.5M0.0%-13%
Ken Griffin · Citadel AdvisorsQ3 2026300,799$10.7M0.0%+13%
Paul Tudor Jones · Tudor Investment CorpQ3 202653,035$1.9M0.0%+267%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CSTL in the last 120 days.

FiledHolderFormStake
Oct 29, 2026PRINCIPAL GLOBAL INVESTORS13G/A4.9%
Oct 29, 2026PRINCIPAL GLOBAL INVESTORS13G/A4.9%

Questions about Castle Biosciences Inc (CSTL) stock

Who owns the most CSTL stock?

The largest reported owner of Castle Biosciences Inc (CSTL) is BlackRock, Inc., with 10.9% of the company. In total, 177 funds and institutions reported holding CSTL at the end of Q2 2026, together about 94% of the shares. See the largest owners.

Are CSTL insiders buying or selling?

In the last 12 months, CSTL insiders reported no open-market purchases and 170 sales worth $18.9M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in CSTL?

As of Oct 30, 2026, 2.11M CSTL shares were sold short, 6.8% of the shares outstanding, up 4.6% from the report before. At the average daily volume of 347,929 shares, buying them all back would take about 6.1 trading days (days to cover). See the history.

Which famous investors hold CSTL?

4 of the 50 well-known investors we track reported CSTL in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $17.6M. See all holders.

Executive pay

Castle Biosciences's chief executive was paid a total of $6.8M for the year ended Dec 31, 2025, down 2% from $6.9M the year before. In the last 12 months, Castle Biosciences's executives and directors bought no stock on the open market and sold $18.9M.

Chief executive, total pay$6.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$13.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.